OncoMatch/Clinical Trials/NCT05581004
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Is NCT05581004 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including RO7502175 and Atezolizumab for locally advanced or metastatic solid tumors.
Treatment: RO7502175 · Atezolizumab · Pembrolizumab — This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Melanoma
Triple-Negative Breast Cancer
Breast Carcinoma
Esophageal Carcinoma
Gastric Cancer
Cervical Cancer
Colorectal Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any anti-cancer therapy
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · San Francisco, California
- University Of Colorado · Aurora, Colorado
- Florida Cancer Specialists - Sarasota · Sarasota, Florida
- Winship Cancer Institute · Atlanta, Georgia
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05581004 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any anti-cancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify